LQDA Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals, Inc. has a net margin of -6.5% compared to Liquidia Corp.'s net margin of -2301.55%. Liquidia Corp.'s return on equity of -221.75% beat Armata Pharmaceuticals, Inc.'s return on equity of --.

Liquidia Corp. has a consensus price target of $39.00, signalling upside risk potential of 30.41%. On the other hand Armata Pharmaceuticals, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 51.52%. Given that Armata Pharmaceuticals, Inc. has higher upside potential than Liquidia Corp., analysts believe Armata Pharmaceuticals, Inc. is more attractive than Liquidia Corp..

Liquidia Corp. has a beta of 0.482, which suggesting that the stock is 51.777% less volatile than S&P 500. In comparison Armata Pharmaceuticals, Inc. has a beta of 1.240, suggesting its more volatile than the S&P 500 by 23.97%.

Liquidia Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Liquidia Corp. pays -- of its earnings as a dividend. Armata Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Liquidia Corp. quarterly revenues are $54.3M, which are larger than Armata Pharmaceuticals, Inc. quarterly revenues of $1.2M. Liquidia Corp.'s net income of -$3.5M is higher than Armata Pharmaceuticals, Inc.'s net income of -$26.7M. Notably, Liquidia Corp.'s price-to-earnings ratio is -- while Armata Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia Corp. is 41.65x versus 49.27x for Armata Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insmed, Inc. has a net margin of -6.5% compared to Liquidia Corp.'s net margin of -259.95%. Liquidia Corp.'s return on equity of -221.75% beat Insmed, Inc.'s return on equity of -193.23%.

Liquidia Corp. has a consensus price target of $39.00, signalling upside risk potential of 30.41%. On the other hand Insmed, Inc. has an analysts' consensus of $220.41 which suggests that it could grow by 6.59%. Given that Liquidia Corp. has higher upside potential than Insmed, Inc., analysts believe Liquidia Corp. is more attractive than Insmed, Inc..

Liquidia Corp. has a beta of 0.482, which suggesting that the stock is 51.777% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.49%.

Liquidia Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Liquidia Corp. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.

Liquidia Corp. quarterly revenues are $54.3M, which are smaller than Insmed, Inc. quarterly revenues of $142.3M. Liquidia Corp.'s net income of -$3.5M is higher than Insmed, Inc.'s net income of -$370M. Notably, Liquidia Corp.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia Corp. is 41.65x versus 88.00x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of -6.5% compared to Liquidia Corp.'s net margin of 13.19%. Liquidia Corp.'s return on equity of -221.75% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

Liquidia Corp. has a consensus price target of $39.00, signalling upside risk potential of 30.41%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 539.54%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Liquidia Corp., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Liquidia Corp..

Liquidia Corp. has a beta of 0.482, which suggesting that the stock is 51.777% less volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.

Liquidia Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Liquidia Corp. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Liquidia Corp. quarterly revenues are $54.3M, which are larger than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Liquidia Corp.'s net income of -$3.5M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Liquidia Corp.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 24.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia Corp. is 41.65x versus 2.19x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

United Therapeutics Corp. has a net margin of -6.5% compared to Liquidia Corp.'s net margin of 42.36%. Liquidia Corp.'s return on equity of -221.75% beat United Therapeutics Corp.'s return on equity of 19.2%.

Liquidia Corp. has a consensus price target of $39.00, signalling upside risk potential of 30.41%. On the other hand United Therapeutics Corp. has an analysts' consensus of $518.25 which suggests that it could grow by 7.75%. Given that Liquidia Corp. has higher upside potential than United Therapeutics Corp., analysts believe Liquidia Corp. is more attractive than United Therapeutics Corp..

Liquidia Corp. has a beta of 0.482, which suggesting that the stock is 51.777% less volatile than S&P 500. In comparison United Therapeutics Corp. has a beta of 0.861, suggesting its less volatile than the S&P 500 by 13.874%.

Liquidia Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United Therapeutics Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Liquidia Corp. pays -- of its earnings as a dividend. United Therapeutics Corp. pays out -- of its earnings as a dividend.

Liquidia Corp. quarterly revenues are $54.3M, which are smaller than United Therapeutics Corp. quarterly revenues of $799.5M. Liquidia Corp.'s net income of -$3.5M is lower than United Therapeutics Corp.'s net income of $338.7M. Notably, Liquidia Corp.'s price-to-earnings ratio is -- while United Therapeutics Corp.'s PE ratio is 18.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia Corp. is 41.65x versus 7.41x for United Therapeutics Corp.. Usually stocks with elevated PS ratios are considered overvalued.